Skip to main content

Proof of concept of prognostic test for critical Septic Patients based in Early Detection of NLRP3 Inflammasome impairment activation.

Project description

Point-of-care testing kit for the early sepsis prognosis

Sepsis causes a systemic inflammatory response driven by proinflammatory cytokines and is the leading cause of death in hospital critical care units. Early disease biomarkers are necessary to assist in the decision-making identification of immunocompromised patients. The development of a point-of-care testing kit to enable quick and reliable detection of immunocompromised patients by using blood biomarkers would improve the early prognosis of sepsis. Recently, an in vitro prognostic product was developed that enables the fast detection of early impairment of the NLRP3 inflammasome activation, as a prognostic biomarker in sepsis. The objective of the current EU-funded SPEDI-TEST project is to demonstrate the technical and commercial feasibility, and evaluate the new business opportunity of the clinical introduction of this novel test.

Field of science

  • /medical and health sciences/clinical medicine/critical care medicine
  • /natural sciences/computer and information sciences/data science/data mining

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA
Address
Calle Luis Fontes Pagan 9 Edif Emi Hospital Reina Sofia
30003 Murcia
Spain
Activity type
Research Organisations
EU contribution
€ 150 000

Beneficiaries (1)

FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA
Spain
EU contribution
€ 150 000
Address
Calle Luis Fontes Pagan 9 Edif Emi Hospital Reina Sofia
30003 Murcia
Activity type
Research Organisations